Our aim was to estimate the prevalence of TERT core promoter mutations in young patients with bladder tumor (first diagnosis at 40 years of age or younger) and to assess the differences in clinical tumor characteristics and disease progression. Here, TERT is linked to urinary bladder neoplasm.